China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020
BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2020.
Fourth Quarter 2020 Financial Highlights
Total sales in the fourth quarter of 2020 increased by 9.7% in USD terms and 3.2% in RMB terms to $112.1 million from $102.2 million in the same quarter of 2019.
Gross profit increased by 16.6% to $74.6 million from $64.0 million in the same quarter of 2019. Gross margin increased to 66.5% from 62.6% in the same quarter of 2019.
Income from operations increased
